β-AR Blockade and CaMKII Activity in HF modifications in HF might provide targets for the development of novel treatments. 1 One of the recently proposed targets in β-AR signaling is Ca 2+ -calmodulin-dependent protein kinase II (CaMKII), a serine threonine kinase with CaMKIIδ being the predominant myocardial isoform. CaMKII becomes activated not only on Ca 2+ /calmodulin binding but also by methionine oxidation, by O-linked glycosylation, by nitrosylation, or by autophosphorylation, which maintains enhanced CaMKII activity independent of Ca 2+ /calmodulin binding. 3 Interestingly, CaMKII protein levels and activity are higher in human failing hearts and numerous experimental models in animals have implicated CaMKII activation in cardiac remodeling, HF progression, and arrhythmias [4] [5] [6] [7] [8] . Consistently, cardiac overexpression of CaMKIIδ C in transgenic mice promotes progressive HF and arrhythmia along with a severely higher mortality, 9 ,10 whereas inhibition or gene deletion of CaMKII has been shown to be beneficial by reducing structural remodeling and abolishing arrhythmias. [11] [12] [13] [14] [15] Recent data indicate a significant crosstalk between β-AR stimulation and CaMKII activation, for example, via protein kinase A (PKA)-dependent increase in cytosolic Ca 2+ or cyclic adenosine monophosphate (cAMP)-dependent activation of Epac. 4 Moreover, CaMKII is suggested to act as a downstream mediator of detrimental β-AR signaling in HF, promoting, for example, proapoptotic effects after catecholaminergic stimulation. 16 However, none of these studies investigated whether the clinical benefit of β-AR blocker might involve a modulation of CaMKII. Here, we determined for the first time the effect of chronic β-AR blocker therapy on CaMKII activity in human and experimental HF.
Methods
The study conformed to the principles outlined in the Declaration of Helsinki, and all procedures were approved by the ethics committees of our institutions. All animal experiments were performed according to the European Community guiding principles in the care and use of animals (2010/63/UE, 22 september 2010) and authorized by the Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit (Germany).
Human Myocardial Samples
Samples of human myocardium were obtained from patients with end-stage HF (dilated or ischemic cardiomyopathy) undergoing cardiac transplantation (Figure 1A Tables I and II in the Data Supplement. The study was approved by the Ethical Committees of the Universities of Göttingen, Regensburg, and Dresden, and all patients gave written informed consent.
CaMKIIδ C Transgenic Mice
For generation of transgenic mice with cardiac-specific CaMKIIδ C overexpression, see a previous study. 10 The mice used for these experiments were bred at the animal facility of the Medical Faculty, Georg August University Göttingen, and the European Neuroscience Institute, Göttingen. Heterozygous CaMKIIδ C transgenic mice on a Black Swiss background were crossed to wild-type (WT) mice on a C57BL/6J background. Transgenic and WT littermates of the F1 generation with a mixed C57BL/6J (50%)×Black Swiss (50%) background were used for this study. All mice were the same strain and groups were sex and age matched for all experiments.
β-AR Blocker Administration in Mice
Metoprolol (Sigma-Aldrich, #M5391) was administered orally via drinking water. For dose establishment experiments, animals were treated with different doses of metoprolol (as indicated). For main experiments, treatment with metoprolol 270 mg/kg*d in CaMKIIδ C transgenic and WT littermates was started at the age of 4 weeks.
Application of Dobutamine for Dose-Response Curves
Mice were kept under light anesthesia (isoflurane, 1.5 vol%) during the whole measurement. Dobutamine was administered intraperitoneally (IP), and the maximum increase in heart rate for each dose was detected using a Vevo 2100 echocardiography setup (Visual Sonics, Inc). The animals used for these experiments had received the applied β-AR blocker dose for at least 1 week before starting the measurements.
Echocardiography
Echocardiographic measurements were performed at several time points, once before (day 0) and 4 times during the metoprolol treatment period (days 3, 10, 24, and 38 after beginning of treatment). Animals were anaesthetized by isoflurane (2 vol%), and light anesthesia was maintained during the whole measurement (isoflurane, 1.5 vol%, under temperature and ECG control). Echocardiography was performed using a Vevo 2100 System (Visual Sonics, Inc) equipped with a 30 MHz transducer, and images were recorded at a frame rate of 300 Hz. Fractional area shortening was calculated from shortaxis B-mode images as (%fractional area shortening)=(endocardial area enddiastolic −endocardial area endsystolic )/endocardial area enddiastolic ×100.
Blood Pressure Measurement
Blood pressure (RR) was measured in awake mice (age 12-14 weeks) by tail cuff method using a Kent Scientific setup with CODA monitor system. After the mice were given a period of 10 minutes to adapt to the animal holders and cuffs, 5 replicate RR values were taken to calculate a mean for each mouse.
ECG Telemetry Recordings
After subcutaneous implantation of ECG transmitters (ETA-F10; Data Sciences International), mice were given a recovery time of 2 weeks before starting the measurement. Long-term ECGs (12 hours overnight) were recorded in freely moving mice (age 12-14 weeks) during physiological conditions using a PhysioTel telemetry setup (Data Sciences International). ECG was recorded and analyzed by Ponemah (Data Sciences International) software including Data Insights. Arrhythmia analysis was performed according to conventional arrhythmia guidelines.
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Biometrical Data
Mice were euthanized at the age of 12 to 14 weeks. Hearts and lungs were immediately explanted and weighed. Heart weight and lung weight were normalized to tibia length.
Histological Analysis
Histological assays were performed as described previously. 19, 20 Briefly, hearts of 12-to 14-week-old mice were rinsed in phosphatebuffered saline, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 3 µm. Sections were deparaffinized and used for the different stainings. To assess the cross-sectional area of cardiomyocytes, sections were stained with 20 µg/mL lectin wheat germ agglutinin fluorescein isothiocyanate (WGA-FITC) (Sigma-Aldrich) β-AR Blockade and CaMKII Activity in HF and mounted with ProlongGold (Invitrogen). For visualization of cardiac fibrosis, sections were stained with DirectRed80 1 hour (SigmaAldrich) for Picro-sirius Red staining to detect collagen. Microscopic images were captured with a digital microscope (IX70; Olympus).
Immunoblot Analysis
Ventricular myocardium of 12-to 14-week-old mice was snapfrozen, pulverized, and lyzed in Kranias buffer (30 mmol/L Tris/ HCl pH 8.8; 5 mmol/L EDTA; 30 mmol/L NaF; 3% SDS; and 10% glycerol+protease inhibitor cocktail+phosphatase inhibitor cocktail; Roche Diagnostics). Protein samples were separated by SDS-PAGE and subsequently transferred to nitrocellulose or polyvinylidene fluoride membranes. Membranes were blocked with Roti-Block (Carl Roth) for 1 hour and afterward incubated with the following antibodies overnight at 4°C: anti-GAPDH (1:1000; Santa Cruz), anti-CSQ (1:1000; ThermoScientific), anti-P-CaMKII-Thr287 (1:1000; ThermoScientific), anti-Ox-CaMKII-Met281/2 (1:1000; Genetex), anti-CaMKII (1:1000; BD Bioscience), anti-P-PLN-Ser16, anti-P-PLN-Thr17, anti-PLN, anti-P-RyR2-Ser2808, anti-P-RyR2-Ser2814 (1:5000; Badrilla), anti-RyR2 (1:2000; Sigma-Aldrich), anti-CnA (1:1000; Millipore), anti-P-CnA-Ser411 (1:1000; generated by Pineda antibodies), anti-HDAC4 (H92; 1:1000; Santa Cruz), anti-P-HDAC4-Ser632 (1:1000; Abcam), anti-LTCCβ2 (1:500; Sigma-Aldrich), anti-Epac1, and anti-Epac2 (1:500; Cell signaling Technology). P-LTCCβ2-Thr498 was detected by P-CaMKII antibody. 21 After incubation with appropriate secondary antibodies for 1 hour, chemiluminescence was detected using a VersaDoc (Biorad) or Fusion FX (Vilber Lourmat) imaging system and quantified with Quantity One (Biorad) or Fusion-Capt (Vilber Lourmat) software.
CaMKII Activity Assay
CaMKII activity was assessed by detecting the amount of CaMKII that binds to GST-HDAC4 amino acids 419 to 670 (containing the CaMKII activity-dependent binding domain). 22 Protein lysates were incubated with glutathione sepharose bead-bound GST-HDAC4-WT (419-670) in high-salt GST-binding buffer (20 mmol/L Tris pH 7.4; 750 mmol/L NaCl; 0.5% NP-40+protease inhibitor cocktail; Roche Diagnostics) for 2 hours at 4°C. The beads were washed 2 times in 500 μL of high-salt GST-binding buffer and 1 time in 500 µL low-salt GST-binding buffer (20 mmol/L Tris pH 7.4; 150 mmol/L NaCl). Bound active CaMKII, CaMKII input, and HDAC4 input were resolved by SDS-PAGE and detected by Western blot using HDAC4 (1:1000; Santa Cruz) and CaMKII antibodies (1:1000; BD Bioscience). Protein loading was normalized to GAPDH (1:10 000; Sigma-Aldrich).
Statistics
Results are presented as means±SEM. Data sets including supplemental figures were compared by Student t test, 1-way ANOVA followed by Newman-Keuls multiple comparison test, 2-way repeated-measures ANOVA followed by Holm-Sidak multiple comparison test, Fisher exact test, or log-rank (Mantel-Cox) test according to the experimental setting. Data sets with unequal variances were compared by Welch t test or Welch ANOVA followed by Games-Howell multiple comparison test. For analysis of dose-response curves, nonlinear regression followed by extra sum-of-squares F test was performed. P values <0.05 were considered statistically significant. For each data set, the respective statistical test is indicated in the figure legend.
Results
Effect of Metoprolol Treatment on CaMKII Activity in HF and Non-HF Patients
First, we compared ventricular myocardium from patients with end-stage HF (ejection fraction ≤37%) who were treated with β-AR blockers with non-β-AR blocker-treated HF patients regarding CaMKII protein levels, CaMKII autophosphorylation, and oxidation, which reflect CaMKII activity. Interestingly, β-AR blocker treatment neither reduced CaMKII expression (normalized to calsequestrin as internal control) Figure 1 . Effect of chronic β-adrenoceptor (β-AR) blocker treatment on CaMKII (calcium/calmodulin-dependent protein kinase II) expression, autophosphorylation, and oxidation in human myocardium. A, Representative immunoblots of P-CaMKII-T287, Ox-CaMKII-M281/2, CaMKII, GAPDH, and calsequestrin (CSQ) of myocardial tissue from heart failure (HF) patients (n=12). B, Quantification (CaMKII normalized to CSQ, P-CaMKII, and Ox-CaMKII normalized to CaMKII). C, Representative immunoblots of P-CaMKII-T287, Ox-CaMKII-M281/2, CaMKII, GAPDH, and CSQ of myocardial tissue from non-HF patients (n=12). D, Quantification. BB indicates β-adrenergic receptor blocker. Statistics: groups were compared by Student's t test. β-AR Blockade and CaMKII Activity in HF nor its autophosphorylation and oxidation ( Figure 1A and 1B) . This was further confirmed by directly assaying CaMKII activity based on histone deacetylase 4 (HDAC4) binding of activated CaMKII ( Figure I in the Data Supplement). 22 In addition, we analyzed the phosphorylation status of prominent CaM-KII downstream targets such as ryanodine receptor 2 (RyR2; at Ser2814), phospholamban (PLN; at Thr17), calcineurin A (CnA; at Ser411), HDAC4 (at Ser632), and L-type Ca 2+ channel β2 (LTCCβ2; at Thr498). All downstream targets showed unchanged CaMKII-dependent phosphorylation ( Figure II in the Data Supplement), reflecting unaltered CaMKII activity in the β-AR blocker-treated patients.
The absence of any obvious CaMKII modulation by β-AR blocker treatment was confirmed in atrial tissue from primarily non-HF subjects undergoing cardiac surgery (aortic valve replacement, aortocoronary bypass and mitral valve repair). Consistently, we could neither observe a change in CaMKII expression, autophosphorylation, and oxidation nor in CaMKII-dependent target phosphorylation in the patients who were treated with β-AR blockers when compared with non-β-AR blocker-treated patients ( The biochemical analysis of human samples involves some well-known limitations. Patients may receive multiple medications, may have different comorbidities, and the cause of disease may vary between individuals. In terms of β-AR blocker treatment, one has also to consider that many patients do not receive an optimal dose and a documented readout for efficient and functional β-AR blockade (like, eg, heart rate reduction) is generally not available. Albeit taking great care to match patient groups to the best of our knowledge (Tables I  and II in the Data Supplement), these rather unexpected findings in human samples prompted us to further evaluate the effect of β-AR blockade on CaMKII in a more standardized manner by using a well-established HF mouse model of cardiac-specific CaMKIIδ C overexpression. 
Metoprolol Treatment in CaMKIIδ C Transgenic Mice
Metoprolol treatment in transgenic and WT littermates was started at the age of 4 weeks, when a decline in cardiac function was already observed in the transgenic mice but not yet associated with a severe HF phenotype. Notably, chronic β-AR blocker therapy in transgenic mice significantly prolonged life span to a median of 18 weeks, whereas untreated transgenic animals showed premature death with a median survival of only 13 weeks (Figure 2A) . To investigate the mechanisms underlying this survival benefit, we examined distinct clinical parameters that reflect the effects of a β-AR blockade. In accordance with the treatment in patients, echocardiographic analysis of cardiac function showed an initial minor negative inotropic effect in both WT and transgenic mice (day 3), which disappeared after chronic β-AR blocker application (10 days). However, long-term β-AR blocker therapy was not able to attenuate the massive decline in contractile parameters observed in the transgenic mice ( Figure 2B ). Nevertheless, during the whole treatment period, there was a significant heart rate reduction in both WT and transgenic mice receiving metoprolol compared with untreated littermates (Δ55.2±7.8 and Δ64.7±4.4 beats per minute; Figure 2C ). In addition to cardiac function, we determined the effect of β-AR blocker treatment on blood pressure. Tail cuff measurements demonstrated a significant decrease in systolic (RR Sys ), diastolic (RR Dia ), and mean arterial blood pressure on metoprolol treatment in WT and transgenic mice (Δ22.5±6.4 and Δ16.6±5.9 mm Hg for RR Sys , Δ12.5±4.6 and Δ13.2±5.2 mm Hg for RR Dia , Δ15.7±4.8 and Δ14.4±5.3 mm Hg for mean arterial blood pressure; Figure 2D ). Next, we analyzed the occurrence of spontaneous arrhythmic events such as premature ventricular contractions and ventricular tachycardia in long-term ECG recordings (12 hours overnight). Transgenic mice showed a massively increased incidence of premature ventricular contractions compared with healthy WT, where arrhythmic events were mostly absent. β-AR blocker treatment could effectively reduce the occurrence of premature ventricular contractions by 70±22% ( Figure 2E and 2F) . Notably, ventricular tachycardias were common events in the untreated transgenic mice (80% of animals), whereas only 1 out of 5 transgenic treated with metoprolol spontaneously developed ventricular tachycardias ( Figure V 
in the Data Supplement).
To analyze the effect of chronic β-AR blockade on cardiac hypertrophy, heart weight was determined and normalized to tibia length. Metoprolol treatment significantly attenuated the marked cardiac hypertrophy observed in transgenic mice (Δ2.6±1.1 mg/mm; Figure 3A ). This reduction in hypertrophic growth was confirmed by histological analysis of cell size (Δ104.5±48.1 µm 2 cross-sectional area; Figure 3C and 3D). Importantly, β-AR blocker reduced backward failure, as metoprolol-treated transgenic mice showed less lung congestion, measured as lung weight normalized to tibia length (Δ2.1±0.9 mg/mm; Figure 3B ). Moreover, β-AR blocker therapy tended to reduce cardiac fibrosis, which was only mildly increased in the transgenic as characterized before ( Figure 3E and 3F ).
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Effect of Metoprolol Treatment on CaMKII Activity and Target Proteins of PKA and CaMKII
The effect of chronic β-AR blocker therapy on CaMKII activity was analyzed in samples from ventricular myocardium. As previously shown for this mouse model, 10 immunoblots revealed an ≈17-fold higher expression level of CaMKII (normalized to calsequestrin as internal control) in the transgenic mice and 2-to 3-fold higher CaMKII autophosphorylation ( Figure -handling proteins such as PLN and RyR2 at their respective PKA phosphorylation sites (PLN at Ser16 and RyR2 at Ser2808) was, however, significantly decreased (−42±9% and −22±7%) in the metoprolol-treated mice ( Figure 4C and 4D) , demonstrating an effective β-AR blockade in our applied model. In line with unaltered CaMKII activity, the phosphorylation of these proteins at their CaMKII phosphorylation sites (PLN at Thr17 and RyR2 at Ser2814) was not significantly affected by chronic β-AR blocker therapy ( Figure 4C and 4D) . In addition, CaMKII-dependent phosphorylation of CnA (at Ser411), HDAC4 (at Ser632), and LTCCβ2 (at Thr498) was unchanged, suggesting that the unaltered CaMKII activity was not restricted to the sarcoplasmic reticulum ( Figure 5A and 5B). Moreover, protein levels of the proposed β-AR signaling/CaMKII crosstalk mediators Epac1 and 2 were not affected by metoprolol treatment ( Figure 5C and 5D) .
To rule out that the observed effects were based on the applied model of forced CaMKII overexpression, in which the capability of CaMKII activity modulation might be limited, we analyzed CaMKII activity also in WT mice treated with metoprolol. Matching our findings from the transgenic mice, β-AR treatment did neither affect the expression nor autophosphorylation and oxidation of CaMKII ( Figure VIII 
Discussion
β-AR blockers are a mainstay in the therapy of HF. However, the mechanisms of their favorable effects still remain poorly understood and in part seem paradoxical because these drugs initially further compromise contractile performance (which was also observed in our mouse model, see Figure 2B ). There is growing evidence that CaMKII is a downstream target of β 1 -AR that mediates detrimental effects of excessive β-AR activation. It has, for example, been reported that β-AR stimulation with isoprenaline induces cardiomyocyte death by activating CaMKII, independent of PKA. 16 In accordance with this finding, mice overexpressing a CaMKII inhibitory peptide were protected from isoprenaline-induced cell death in vivo. 13 In addition, recent studies using CaMKII knockout mice demonstrated that development of HF and fibrosis in response to chronic isoproterenol treatment is mediated through its effects on CaMKII.
14 On the basis of these observations, blocking β-AR signaling would be expected to reduce CaMKII activation and its downstream cellular effects. Notable studies using specific β 1 -AR and β 2 -AR knockout mice showed only β 1 -AR knockout mice were resistant to CaMKII activation and cell death after myocardial infarction. 23 This suggested that β 1 -AR blocker treatment in particular would attenuate the detrimental effects of CaMKII overactivity, a finding that would imply that the beneficial effects of β-AR blockers are in part because of inhibition of CaMKII activation.
Surprisingly, in our study, we did not observe alterations in CaMKII expression, activity, or downstream target phosphorylation in samples from end-stage HF patients on β-AR blocker therapy (Figure 1 ; Figure I and II in the Data Supplement; Table I in the Data Supplement). We reassessed Table II in the Data Supplement).
In this patient collective, we again could not detect an effect of β-AR blocker therapy on CaMKII activity, indicating that the absence of CaMKII modulation by β-AR blocker treatment is not confined to end-stage HF. Given the limitations of human samples like different comorbidities of the patients, partly undocumented or uncontrolled clinical parameters, and different β-AR blocker doses, we reevaluated these results under more controlled and standardized conditions by applying β-AR blocker treatment in a mouse model of HF driven by CaMKII overexpression. Beneficial effects of oral metoprolol treatment in mice have been described for a broad range of doses from 2.5 to 350 mg•kg
. 24, 25 Moreover, it has been shown that the cardiovascular response to β-AR stimulation and blockade depends much on the mouse strain, 26 which was also obvious in our preliminary tests on dose finding (data not shown). Thus, we put special emphasis on establishing an effective metoprolol dose ( Figure IV in the Data Supplement). As internal control of effective β-AR blockade, we could observe typical β-AR blocker effects like heart rate and blood pressure reduction in our applied mouse model ( Figure 2 ) and moreover-on a molecular level-a significant decrease in PKA downstream target phosphorylation (Figure 4 ; Figure VIII in the Data Supplement).
In this mouse model of CaMKII-induced HF, metoprolol indeed had beneficial effects on survival, development of cardiac hypertrophy, and arrhythmia susceptibility (Figures 2 and  3 ; Figure V in the Data Supplement). We were not able to detect any additional benefits on echocardiographic cardiac contractility, thus our data suggest that the well-known antiarrhythmic effect of β-AR blocker therapy likely contributed to improved survival. Yet, we observed less pulmonary congestion in the Figure 4 . Impact of chronic β-adrenoceptor (β-AR) blockade on CaMKII (calcium/calmodulin-dependent protein kinase II) activity and target phosphorylation of protein kinase A and CaMKII in CaMKIIδ C transgenic (TG) mice. A, Representative immunoblots of P-CaMKII-T287, Ox-CaMKII-M281/2, CaMKII, GAPDH, and calsequestrin (CSQ) of myocardial tissue from CaMKIIδ C TG mice with and without metoprolol treatment. B, Quantification (P-CaMKII and Ox-CaMKII normalized to CaMKII). C, Representative immunoblots of P-RyR2-S2808, P-RyR2-S2814, RyR2, P-PLN-S16, P-PLN-T17, PLN, GAPDH, and CSQ. D, Quantification (P-RyR2-S2808 and P-RyR2-2814 normalized to RyR2, P-PLN-S16, and P-PLN-T17 normalized to PLN). Meto indicates metoprolol. n≥11. Statistics: Groups were compared by Student's t test. *P<0.05 vs H 2 O. β-AR Blockade and CaMKII Activity in HF metoprolol-treated mice ( Figure 3B ), suggesting some clinical benefit beyond survival and arrhythmogenesis, potentially because of lower afterload (lower blood pressure) and reduced hypertrophy. These findings are consistent with clinical 27 and experimental data, 25 showing that β-AR blockade primarily induces structural reverse remodeling. Importantly, CaMKII activity and CaMKII target phosphorylation were unaffected by β-AR blockade (Figures 4 and 5) , which matched our findings in human samples. In contrast, PKA target phosphorylation was significantly decreased on metoprolol treatment (Figure 4 ). This indicates that there are PKA-dependent and CaMKIIindependent elements of cardiac disease in this model, which might in part account for the development of the cardiomyopathic phenotype and are susceptible to β-AR blocker treatment.
One potential limitation of overexpressed CaMKII is that increased enzyme abundance may defy cellular regulatory mechanisms because of, for example, a shift in protein-protein interaction or changes in localization. Our data do not support this assumption. First, despite a 17-fold increase in CaMKII expression, we observed only 2-to 3-fold higher autophosphorylation ( Figure VI in the Data Supplement). This clearly reflects that the enzyme is not constitutively activated and hence still subjected to cellular control mechanisms. A possible caveat of this constellation is that the majority of CaMKII is inactive instead and thereby exerts dominant negative effects. Contrasting this thesis, higher phosphorylation levels of CaMKII targets in this model shown by others (PLN at T17 10 and RyR2 at S2814 28 ) and us (CnA at S411 and HDAC4 at S632; Figure X in the Data Supplement) indicate that overall the overexpressed CaMKII is functional. Finally, our data on β-AR blockade in WT mice support our conclusion that β-AR blocker therapy does not target CaMKII activity. Metoprolol showed no impact on endogenous CaMKII expression, autophosphorylation, and oxidation and CaMKII-dependent target phosphorylation (Figures VIII and IX in the Data Supplement), indicating that the lack of CaMKII activity modulation by β-AR blockers is not restricted to the applied model of CaMKII overexpression.
Taken together, our data suggest that treatment with β-AR blockers is unexpectedly not associated with a modulation of CaMKII. Thus, our findings further promote the view that CaMKII is not effectively targeted by current therapeutic approaches in HF. Directly targeting CaMKII activity may, therefore, be an additional option complementing the effects of β-AR blockers in HF therapy. Figure 5 . Impact of chronic β-adrenoceptor (β-AR) blockade on additional CaMKII (calcium/calmodulin-dependent protein kinase II) target phosphorylation and Epac expression in CaMKIIδ C transgenic (TG) mice. A, Representative immunoblots of P-CnA-S411, CnA, P-HDAC4-S632, HDAC4, P-LTCCβ2-T498, P-LTCCβ2, GAPDH, and calsequestrin (CSQ) of myocardial tissue from CaMKIIδ C TG mice with and without metoprolol treatment. B, Quantification (P-CnA-S411 normalized to CnA, P-HDAC4-S632 normalized to HDAC4, P-LTCCβ2-T498 normalized to LTCCβ2). C, Representative immunoblots of Epac1, Epac2, GAPDH, and CSQ. D, Quantification (Epac1 and Epac2 normalized to CSQ). Meto indicates metoprolol. n=11. Statistics: groups were compared by Student's t test.
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